Evidence map›Paper›PMID 42502280›Full record

ArticleEJHaem2026

Real-World Treatment Patterns and Physician Perspectives in Relapsed/Refractory Multiple Myeloma: Results From a Nationwide Italian GIMEMA Survey.

Francesca Fazio, Alfonso Piciocchi, Paolo de Fabritiis, Messina Messina, Stefano Soddu, Valeria Sargentini, Francesco Di Raimondo, Francesca Patriarca, Pellegrino Musto, Maurizio Offidani and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Francesca FazioHematology Department of Translational and Precision Medicine Sapienza University of Rome-Azienda Policlinico Umberto I Rome Italy.
Alfonso PiciocchiHematology Department of Translational and Precision Medicine Sapienza University of Rome-Azienda Policlinico Umberto I Rome Italy.
Paolo de FabritiisGIMEMA Foundation Rome Italy.
Messina MessinaGIMEMA Foundation Rome Italy.
Stefano SodduGIMEMA Foundation Rome Italy.
Valeria SargentiniGIMEMA Foundation Rome Italy.
Francesco Di RaimondoHematology Unit and BMT AOU Policlinico G. Rodolico - S. Marco Università di Catania Catania Italy.
Francesca PatriarcaHematology and Transplant Center Unit Azienda Sanitaria Universitaria Friuli Centrale DMED Udine University Udine Italy.
Pellegrino MustoUnit of Hematology and Stem Cell Transplantation AOUC Policlinico Bari "Aldo Moro" University School of Medicine Department of Precision and Regenerative Medicine and Ionian Area Bari Italy.
Maurizio OffidaniClinica Di Ematologia AOU delle Marche Ancona Italy.
Elena ZamagniDepartment of Medical and Surgical Sciences University of Bologna Bologna Italy.
Sara BringhenHematology ASO Santa Croce e Carle di Cuneo Cuneo Italy.
Massimo GentileHematology Unit, Azienda Ospedaliera Annunziata Cosenza Italy.
Giuseppe MeleU.O.C. di Ematologia-Unità Trapianto di Midollo Osseo PO Antonio Perrino Brindisi Italy.
Paola FaziGIMEMA Foundation Rome Italy.
MariaTeresa PetrucciHematology Department of Translational and Precision Medicine Sapienza University of Rome-Azienda Policlinico Umberto I Rome Italy.
Michele CavoDepartment of Medical and Surgical Sciences University of Bologna Bologna Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The management of relapsed/refractory multiple myeloma (RRMM) remains complex due to early exposure to multiple drug classes since the first treatment line. Aims: To evaluate treatment patterns and identify unmet clinical needs in RRMM across Italian hematology centers. Methods: A national survey was conducted among hematologists experienced in MM care and working in 71 centers, collecting aggregated data on treatment lines, regimens, and clinician perceptions. Results: Upfront daratumumab-based regimens were used most frequently. Lenalidomide and anti-CD38 refractoriness emerged early, limiting options in 2L/3L. Anti-BCMA therapies were broadly endorsed. Conclusions: Despite therapeutic advances for MM, real-world data reveal significant treatment variability and reinforce the need for shared guidelines and innovative therapies.

Indexed as

multiple myelomareal‐worldrelapsed/refractory multiple myeloma

Identifiers

PMID42502280
PMCPMC13401147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.